The U.S. Department of Agriculture (USDA) recently released guidelines for processing federal loans for the hemp industry. Since hemp was federally legalized under the 2018 Farm Bill, it is now considered an agricultural commodity like any other crop...
A scientist in a case that forced the release of a previously “secret” Justice Department document about federally authorized marijuana research this week is now calling on Congress to urge administrative action to more rapidly expand studies into the therapeutic potential of cannabis.
In today's tech-heavy world, cannabis is not the put-it-in-your-pipe-and-smoke-it substance we were all used to for so long. Now, there is technology for nearly everything, and weed is no different.
Legalization advocates have long argued that marijuana represents a potentially effective treatment option for chronic pain and could serve as an alternative to opioid-based painkillers—and according to a new scientific meta-analysis, they may be onto something.
The Food and Drug Administration (FDA) recently announced a policy change that will expedite the marketing of marijuana testing devices if they’re used for certain purposes.
We’ve seen our share of ups and downs in the market, but is this the year the gains finally halt and the floor falls out? Short answer: no.
The cannabis industry's growth potential is one of the key reasons investors have been buying up pot stocks in recent years.
The state gave four more medical marijuana dispensaries permission to sell recreational weed, starting Jan. 1.
In just a few weeks, Illinoisans will be able to buy recreational marijuana from pot shops across the state. So where can you buy weed, how much can you have, and where will you be able to light up? We answered these questions and more.
With the cannabis industry reeling from a series of setbacks over the last six months, the marijuana business conference began in Las Vegas on Monday with an investors’ meet-up marked by existential distress.
Industrial hemp is poised to be a fast growing sector of agriculture in Virginia.
If you want to make money in stocks, look forward, not backward.
GW Pharmaceuticals PLC reported Tuesday afternoon that sales of its cannabis-derived epilepsy drug more than doubled from the previous quarter, sending shares spiking more than 11% higher in after-hours trading.
Surprising news from Flowr Corp looks bad, but could signal a turnaround in cannabis stocks is near.
After 10 years of conventional medications left her bed-ridden, medicinal cannabis fully restored this mother's life
